The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis: A systematic review

Rajalingham Sakthiswary*, Srijit Das

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF α antagonists treatment and suppression of bone resorption.

Original languageEnglish
Pages (from-to)1552-1557
Number of pages6
JournalCurrent Drug Targets
Volume14
Issue number13
DOIs
Publication statusPublished - Dec 2013
Externally publishedYes

Keywords

  • Bone mineral density
  • Osteoporosis
  • Rheumatoid arthritis
  • TNF α antagonists

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this